

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 August 2011 (25.08.2011)

PCT

(10) International Publication Number
WO 2011/103546 A1

(51) International Patent Classification:
A01N 43/64 (2006.01) *A61K 31/41* (2006.01)

Road, P. O. Box 1539, King Of Prussia, PA 19406-0939 (US).

(21) International Application Number:
PCT/US2011/025661

(22) International Filing Date:
22 February 2011 (22.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/306,709 22 February 2010 (22.02.2010) US
61/357,587 23 June 2010 (23.06.2010) US

(71) Applicant (for all designated States except US): **GLAXOSMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ADAMS, Nicholas, D.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **AQUINO, Christopher, Joseph** [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US). **CHAUDHARI, Amita, M.** [CA/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **GHERGUROVICH, Jonathan, M.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **KIESOW, Terence, John** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **PARRISH, Cynthia, A.** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **REIF, Alexander, Joseph** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **WIGGALL, Kenneth** [GB/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US).

(74) Agents: **PENG, Tony, W.** et al.; Glaxosmithkline, Corporation Intellectual Property, Uw2220, 709 Swedeland

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS

(57) Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.



WO 2011/103546 A1